References
- Waddington-Cruz M, Ackermann EJ, Polydefkis M, et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial. Amyloid. 2018;25(3):180–188.
- Lopes A, Rodrigues C, Fonseca I, et al. Family dynamics in transthyretin-related familial amyloid polyneuropathy Val30Met: does genetic risk affect family functioning? Clin Genet. 2018;94(5):401–408.
- Hawkins PN, Ando Y, Dispenzeri A, et al. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015;47(8):625–628.
- Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.
- Dungu JN, Anderson LJ, Whelan CJ, et al. Cardiac transthyretin amyloidosis. Heart. 2012;98(21):1546–1574.
- Hanna M. Novel drugs targeting transthyretin amyloidosis. Curr Heart Fail Rep. 2014;11(1):50–57.
- Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10(12):1086–1097.
- Koike H, Misu K, Ikeda S, et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol. 2002;59(11):1771–1776.
- Buxbaum JN. Oligonucleotide drugs for transthyretin amyloidosis. N Engl J Med. 2018;379(1):82–85.
- Yokoyama T, Mizuguchi M. Inhibition of the amyloidogenesis of transthyretin by natural products and synthetic compounds. Biol Pharm Bull. 2018;41(7):979–984.
- Lavigne-Moreira C, Marques VD, Gonçalves MVM, et al. The genetic heterogeneity of hereditary transthyretin amyloidosis in a sample of the Brazilian population. J Peripher Nerv Syst. 2018;23(2):134–137.
- Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286–1290.
- Koike H, Nakamura T, Nishi R, et al. Widespread cardiac and vasomotor autonomic dysfunction in Non-Val30Met hereditary transthyretin amyloidosis. Intern Med J. 2018;57(23):3365–3370.
- Kulkarni JA, Cullis PR, van der Meel R. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther. 2018;28(3):146–147.
- U.S. Food and Drug Administration. ONPATTRO (patisiran) lipid complex injection, for intravenous use. [ cited 2018 Sep 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210922s000lbl.pdf
- European medicines agency. Onpattro (patisiran) An overview of Onpattro and why it is authorised in the EU. [ cited 2018 Oct 31]. Available from: https://www.ema.europa.eu/documents/overview/onpattro-epar-medicine-overview_en.pdf
- Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet. 1993;341(8853):1113–1116.
- Adams D, Samuel D, Goulon-Goeau C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain. 2000;123(7):1495–1504.
- Rocha A, Lobato L. Liver transplantation in transthyretin amyloidosis: characteristics and management related to kidney disease. Transplant Rev (Orlando). 2017;31(2):115–120.
- Ericzon BG, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99(9):1847–1854.
- Kerschen P, Planté-Bordeneuve V. Current and future treatment approaches in transthyretin familial amyloid polyneuropathy. Curr Treat Options Neurol. 2016;18(12):53.
- Maia LF, Magalhães R, Freitas J, et al. CNS involvement in V30M transthyretin amyloidosis: clinical,neuropathological and biochemical findings. J Neurol Neurosurg Psychiatry. 2015;86(2):159–167.
- Adams D, Cauquil C, Labeyrie C, et al. TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies. Expert Opin Pharmacother. 2016;17(6):791–792.
- Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: arandomized clinical trial. JAMA. 2013;310(24):2658–2667.
- Johnson SM, Connelly S, Fearns C, et al. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to aregulatory-agency-approved drug. J Mol Biol. 2012;421(2–3):185–193.
- Monteiro C, Martins Da Silva A, Ferreira N, et al. Cerebrospinal fluid and vitreous body exposure to orally administeredtafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients. Amyloid. 2018;25(2):120–128.
- Coelho T, Maia LF, Martins Da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: arandomized, controlled trial. Neurology. 2012;79(8):785–792.
- Barroso FA, Judge DP, Ebede B, et al. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloidpolyneuropathy: resultsup to 6 years. Amyloid. 2017;24(3):194–204.
- Coelho T, Merlini G, Bulawa CE, et al. Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther. 2016;5(1):1–25.
- Keam SJ. Inotersen: first global approval. Drugs. 2018;78(13):1371–1376.
- Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22–31.
- U.S. Food and Drug Administration. ONPATTRO (patisiran) lipid complex injection, for intravenous use. [ cited Sep 15 2018]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210922Orig1s000ChemR.pdf
- Gonçalves P, Martins H, Costelha S, et al. Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model. Amyloid. 2016;23(4):249–253.
- Butler JS, Chan A, Costelha S, et al. Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid. 2016;23(2):109–118.
- Haussecker D, Kay MA. RNA interference. Drugging RNAi. Science. 2015;347(6226):1069–1070.
- Walker S. New medications in the treatment of hereditary transthyretin amyloidosis. Hosp Pharm. 2018;53(4):236–238.
- U.S. Food and Drug Administration. ONPATTRO (patisiran) lipid complex injection, for intravenous use. [ cited Sep 15, 2018]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210922Orig1s000MultiR.pdf.
- Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369(9):819–829.
- Suhr OB, Coelho T, Buades J, et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis. 2015;10:109.
- Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.
- ClinicalTrials.cov. The study of an investigational drug, patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-mediated amyloidosis in patients who have already been treated with ALN-TTR02 (Patisiran). [ cited Sep 152018]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02510261?term=NCT02510261&rank=1
- Titze-de-Almeida R, David C, Titze-de-Almeida SS. The race of 10 synthetic RNAi-based drugs to the pharmaceutical market. Pharm Res. 2017;34(7):1339–1363.